SG10201700198VA - Laquinimod formulations without alkalizing agent - Google Patents
Laquinimod formulations without alkalizing agentInfo
- Publication number
- SG10201700198VA SG10201700198VA SG10201700198VA SG10201700198VA SG10201700198VA SG 10201700198V A SG10201700198V A SG 10201700198VA SG 10201700198V A SG10201700198V A SG 10201700198VA SG 10201700198V A SG10201700198V A SG 10201700198VA SG 10201700198V A SG10201700198V A SG 10201700198VA
- Authority
- SG
- Singapore
- Prior art keywords
- alkalizing agent
- laquinimod
- formulations
- laquinimod formulations
- alkalizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201700198VA true SG10201700198VA (en) | 2017-02-27 |
Family
ID=49914501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407688QA SG11201407688QA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
| SG10201700198VA SG10201700198VA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407688QA SG11201407688QA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (en) |
| EP (1) | EP2872141A4 (en) |
| JP (1) | JP2015527321A (en) |
| KR (1) | KR20150036553A (en) |
| CN (1) | CN104470519A (en) |
| AR (1) | AR091706A1 (en) |
| AU (1) | AU2013290274A1 (en) |
| BR (1) | BR112015000321A2 (en) |
| CA (1) | CA2873230A1 (en) |
| EA (1) | EA201590193A1 (en) |
| HK (1) | HK1209054A1 (en) |
| IL (1) | IL236229A0 (en) |
| MX (1) | MX2015000398A (en) |
| NZ (1) | NZ630241A (en) |
| SG (2) | SG11201407688QA (en) |
| TW (1) | TW201408299A (en) |
| UA (1) | UA115555C2 (en) |
| WO (1) | WO2014011750A1 (en) |
| ZA (1) | ZA201500287B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2234485T3 (en) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stable laquinimod preparations |
| AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
| TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
| TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
| JP2015535287A (en) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod amine salt |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| JP2017514824A (en) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with high disability |
| CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
| CN107823168A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | A kind of rapidly-soluble tablet and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (en) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| CN101291911B (en) * | 2005-10-19 | 2014-08-13 | 泰华制药工业有限公司 | Crystals of laquinimod sodium, and process for the manufacture thereof |
| WO2007146248A2 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| PL2234485T3 (en) * | 2007-12-20 | 2014-06-30 | Teva Pharma | Stable laquinimod preparations |
| EP2376456A2 (en) * | 2008-12-17 | 2011-10-19 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| CA2843432A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/en unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en active Application Filing
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/en not_active Application Discontinuation
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/en unknown
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/en active Pending
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/en active Pending
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 EA EA201590193A patent/EA201590193A1/en unknown
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/en active Search and Examination
- 2013-10-07 UA UAA201413984A patent/UA115555C2/en unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
- 2015-10-08 HK HK15109818.4A patent/HK1209054A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL236229A0 (en) | 2015-01-29 |
| US20140018386A1 (en) | 2014-01-16 |
| TW201408299A (en) | 2014-03-01 |
| EP2872141A4 (en) | 2016-01-13 |
| KR20150036553A (en) | 2015-04-07 |
| BR112015000321A2 (en) | 2017-06-27 |
| UA115555C2 (en) | 2017-11-27 |
| SG11201407688QA (en) | 2014-12-30 |
| ZA201500287B (en) | 2016-10-26 |
| AR091706A1 (en) | 2015-02-25 |
| CN104470519A (en) | 2015-03-25 |
| MX2015000398A (en) | 2015-04-10 |
| HK1209054A1 (en) | 2016-03-24 |
| JP2015527321A (en) | 2015-09-17 |
| WO2014011750A8 (en) | 2014-12-04 |
| WO2014011750A1 (en) | 2014-01-16 |
| CA2873230A1 (en) | 2014-01-16 |
| EA201590193A1 (en) | 2015-04-30 |
| EP2872141A1 (en) | 2015-05-20 |
| NZ630241A (en) | 2017-09-29 |
| AU2013290274A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212701A1 (en) | Formulations of enzalutamide | |
| TWI563077B (en) | Cleaning formulations | |
| HK1203812A1 (en) | Novel pharmaceutical formulations | |
| HK1209054A1 (en) | Laquinimod formulations without alkalizing agent | |
| HK1205679A1 (en) | Nicotine formulation | |
| PT2908835T (en) | Stable formulations | |
| IL234747A0 (en) | Vesicular formulations | |
| HK1207290A1 (en) | Oral formulation | |
| IL235988B (en) | Genotype- or phenotype-based pharmaceutical formulations | |
| PL2908859T3 (en) | Aripiprazole formulations | |
| HK1209339A1 (en) | Pharmaceutical formulations | |
| HK1202249A1 (en) | Vesicular formulations | |
| GB201211406D0 (en) | Pharmaceutical formulations | |
| GB201211403D0 (en) | Pharmaceutical formulations | |
| IL234771B (en) | Nicotine formulation | |
| GB201206178D0 (en) | Formulations |